<ѻý>Guselkumab Response Durable in Psoriatic Arthritisѻý> Skin and joint improvements persisted through 2 years of follow-up Nov 08, 2021
<ѻý>Early Biologics Better in Juvenile Idiopathic Arthritisѻý> After 2 years, more patients on combo biologic/DMARD regimen had inactive disease Nov 08, 2021
<ѻý>Brepocitinib Shows Promise in Phase II Trial for PsAѻý> Oral tyrosine kinase 2/JAK-1 inhibitor improved both joint and skin manifestations Nov 07, 2021
<ѻý>Targeting IL-23 Succeeds in Psoriatic Arthritisѻý> Patients had active, longstanding disease and inadequate responses to other agents Nov 07, 2021
<ѻý>Can Abatacept Reverse Early Rheumatoid Arthritis?ѻý> At-risk patients showed improvements in inflammation -- and also delays in disease onset Nov 06, 2021
<ѻý>No Love for PRP in Ankle Osteoarthritis Trialѻý> Dutch researchers throw cold water on popular therapy Oct 26, 2021
<ѻý>How Should Patients With Autoimmune Diseases Approach COVID Vaccination?ѻý> Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
<ѻý>First Interchangeable Humira Biosimilar Approvedѻý> Cyltezo nabs coveted "interchangeable" status for RA, inflammatory bowel disease, and more Oct 18, 2021
<ѻý>In RA, Little Risk for Recurrent Cancer With Biologic Treatmentѻý> Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<ѻý>Statins Not Linked With Rheumatoid Arthritis, Large Study Findsѻý> Risks attenuated after adjustment for lipid levels Sep 22, 2021
<ѻý>IBD and Pediatric Arthritis: Exploring the Linkѻý> Risk factors include enthesitis, family history, and etanercept use Sep 15, 2021
<ѻý>Lymphoma in RA: Disease Activity Mattersѻý> Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
<ѻý>FDA Slaps Restrictions on JAK Inhibitors Over Serious Safety Risksѻý> Use for inflammatory conditions limited to those who fail on TNF blockers Sep 01, 2021
<ѻý>What Factors Predict RA in First-Degree Relatives?ѻý> Study may offer insight into preclinical phase to identify factors that predict progression Aug 12, 2021
<ѻý>New-Onset IBD and IL-17 Inhibitors: What Is the Risk?ѻý> Underlying inflammatory disease severity should be taken into account Jul 21, 2021
<ѻý>CV Risk in PsA: Do Drugs Matter?ѻý> Study weighs in on heart safety of TNF inhibitors versus other biologics Jul 19, 2021
<ѻý>Effective Treatments for Hand Osteoarthritis: The Search Goes Onѻý> Hydroxychloroquine not effective as disease-modifying drug for erosive hand OA, trial confirmed Jul 08, 2021
<ѻý>Rinvoq Shows Promise in Spine Diseaseѻý> 1-year results in ankylosing spondylitis demonstrate efficacy for JAK inhibitor upadacitinib Jul 02, 2021
<ѻý>Target TNF or IL-12/23 in Psoriatic Arthritis?ѻý> Both TNF inhibitors and ustekinumab were effective in real-world use Jun 30, 2021
<ѻý>New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexateѻý> Many RA patients succeed with optimized use of the DMARD before adding another medication Jun 28, 2021
<ѻý>Pain Persists in RA, Even Without Inflammationѻý> At 5 years, one-third of patients with rheumatoid arthritis still had "unacceptable" pain Jun 22, 2021
<ѻý>Osteoarthritis: A Link With Parkinson's?ѻý> Inflammation may contribute to both joint and nerve degeneration Jun 09, 2021
<ѻý>Secukinumab Shows Promise for Kids With Arthritisѻý> More than 90% responded at week 12, study showed Jun 07, 2021
<ѻý>Rituximab a Hazard in RA Patients With COVIDѻý> Poor outcomes were fourfold higher among rituximab users than for those on TNF inhibitors Jun 03, 2021
<ѻý>Methotrexate Impairs COVID Vax Responseѻý> Can extra vaccine doses or discontinuing drug benefit patients with immune-mediated diseases? May 25, 2021
<ѻý>Plaque Psoriasis Drug Shows Promise for Psoriatic Arthritisѻý> Monoclonal antibody targets the IL-23 p19 subunit May 20, 2021
<ѻý>For Safety, One Biologic a Winner in Psoriasis, Psoriatic Arthritisѻý> Lower hospitalization rates compared with other biologics or small molecule therapies May 19, 2021
<ѻý>Stopping IL-17 Drug for Axial Spondyloarthritis? Expect Spinal Flaresѻý> But low disease activity regained if treatment restarted May 11, 2021
<ѻý>The Death of One Little Girl Helped Millionsѻý> A case more than 35 years ago has spurred discoveries ever since May 07, 2021 podcast
<ѻý>Results Disappoint for Fecal Transplant in Arthritisѻý> But interest persists in targeting the gut-joint axis in psoriatic arthritis May 04, 2021
<ѻý>Pegloticase Safe for Dialysis Patients With Goutѻý> Significant drop in monthly ESA dose seen after treatment, too Apr 09, 2021
<ѻý>For Enthesitis in Psoriatic Arthritis, Target IL-23ѻý> Targeted agent provides relief for many PsA patients Apr 08, 2021
<ѻý>JAK Inhibitor Promising in Psoriatic Arthritisѻý> Oral agent noninferior to adalimumab in joint symptoms Apr 01, 2021
<ѻý>FDA Panel Unhappy With Novel OA Pain Drugѻý> Latest setback for troubled osteoarthritis biologic Mar 25, 2021
<ѻý>Don't Stop Taltz in Psoriatic Arthritisѻý> Significantly more patients relapsed, and more quickly, after withdrawal Mar 10, 2021
<ѻý>JAK Inhibitor a Hit With RA Patientsѻý> Superior to adalimumab on many patient-reported outcomes Feb 26, 2021
<ѻý>JAK Inhibitor Misses Endpoint in Safety Study. Now What?ѻý> Major blow to popular class of oral rheumatology drugs Jan 27, 2021
<ѻý>PET Scans Reveal Vascular Inflammationѻý> In giant cell arteritis, imaging confirmed clinical response Jan 07, 2021
<ѻý>Spinal Benefits Seen With Cosentyx in PsAѻý> First trial to evaluate response of axial symptoms in psoriatic arthritis to biologic treatment Dec 22, 2020